- Relay buys AI startup to aid unorthodox drug discovery questby Ned Pagliarulo on Aprile 16, 2021 at 4:15 pm
The $85 million acquisition is an unusual and early step for a company like Relay, which went public last July and only just began clinical testing of its lead drugs last year.
- US clears AstraZeneca buyout of Alexion amid closer scrutiny of biopharma M&Aby Jonathan Gardner on Aprile 16, 2021 at 3:53 pm
FTC authorization of the $39 billion deal — the sector's largest in 2020 — may ease concerns over the agency's plans to more intently inspect pharma deals.
- Lilly asks FDA to revoke clearance of first COVID-19 antibody drugby Ben Fidler on Aprile 16, 2021 at 3:49 pm
The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug.
- AI drug prospector Recursion bumps IPO up (again) to $374Mby Amirah Al Idrus on Aprile 16, 2021 at 2:42 pm
AI drug prospector Recursion bumps IPO up (again) to $374M aalidrus Fri, 04/16/2021 - 10:42
- Could this common heart drug defeat obesity by preventing inflammation?by Arlene Weintraub on Aprile 16, 2021 at 12:18 pm
Could this common heart drug defeat obesity by preventing inflammation? arlene.weintraub Fri, 04/16/2021 - 08:18
- Precision reacquires rights to allogeneic CAR-Ts from Servierby Nick Paul on Aprile 16, 2021 at 11:47 am
Precision reacquires rights to allogeneic CAR-Ts from Servier ntaylor Fri, 04/16/2021 - 07:47
- EMA starts review of GSK and Vir's COVID-19 antibody therapyby Nick Paul on Aprile 16, 2021 at 10:39 am
EMA starts review of GSK and Vir's COVID-19 antibody therapy ntaylor Fri, 04/16/2021 - 06:39
- Rapha Capital Management launches $100M life science VC fund with an eye on early scienceby Ben Adams on Aprile 16, 2021 at 7:25 am
Rapha Capital Management launches $100M life science VC fund with an eye on early science badams Fri, 04/16/2021 - 03:25
- Chutes & Ladders—Lilly, bidding adieu to Shah, lines up Apple exec as CDOby Fraiser Kansteiner on Aprile 16, 2021 at 3:52 am
Chutes & Ladders—Lilly, bidding adieu to Shah, lines up Apple exec as CDO fkansteiner Thu, 04/15/2021 - 23:52
- Citing Variants, Eli Lilly Asks FDA To Revoke EUA for Single Antibody Therapyon Aprile 16, 2021 at 12:00 am
The reason for the request was the monotherapy antibody therapy is less effective against the COVID-19 variants, such as have risen from the U.K., South Africa and Brazil, as well as the growing B.1.427/B.1.429 California variant.
- Relay Therapeutics Snaps up ZebiAI with $85 Million Upfront Paymenton Aprile 16, 2021 at 12:00 am
In an effort to boost drug discovery for the “toughest drug discovery problems” through the use of machine learning, precision medicines company Relay Therapeutics is acquiring Waltham, Mass.-based ZebiAI with an $85 million upfront payment.
- Pacira Takes ASA to Court in Defense of Non-Opioid Painkilleron Aprile 16, 2021 at 12:00 am
With its only approved drug product on the line, Pacira Biosciences is fighting back against what it's calling “misrepresentation of the clinical effectiveness” of its non-opioid pain reliever Exparel.
- Monkey-Human Hybrid Research Offers Promise, but Sparks Ethical Debateon Aprile 16, 2021 at 12:00 am
According to the researchers, who published their findings online in Cell, certain experiments can't be conducted in humans, making nearly human hybrids a possible solution to this investigational barrier.
- Abzena Plans $200 Million Manufacturing Biologics Facility in N.C.on Aprile 16, 2021 at 12:00 am
Abzena is opening another manufacturing site, its sixth in a global network. This morning, the partner research organization announced it would build a $200 million facility in Sanford, N.C.
- TG Therapeutics Touts Additional Positive Data, Plans Regulatory Submission for MS Drugon Aprile 16, 2021 at 12:00 am
TG Therapeutics is on track for a regulatory submission for anti-CD20 antibody ublituximab next quarter, on the back of new Phase III data showing it reduces relapses and brain lesions in patients with relapsing forms of multiple sclerosis (MS).
- BioSpace Movers & Shakers, April 16on Aprile 16, 2021 at 12:00 am
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
- Research Roundup: UK Variant Not as Lethal as Originally Reported and Moreon Aprile 16, 2021 at 12:00 am
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
- Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigensby Mark Zipkin on Aprile 15, 2021 at 3:48 pm
The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of personalized cancer immunotherapies that target proteins unique to an individual’s tumor. Neoantigen-focused companies have closed smaller initial public offerings (IPOs) in the past. Two major examples in 2018 were an €80M ($95.6M) net raise for the US firm Gritstone Oncology and a €75.2M ($89.9M) IPO for its compatriot Neon Therapeutics. But the Achilles close, following a series of fundraising announcements over the past six months for younger neoantigen companies, could be a sign that investors are warming up as never before. Investors had soured on the neoantigen space following some late-stage clinical failures in therapies targeting tumor-associated antigens (TAAs), says Cedric Bogaert, co-founder and CEO of myNEO, a bioinformatics company in Belgium that identifies neoantigens. TAAs are commonly present in multiple types of tumors, making them attractive therapeutic targets for drug developers. But some can also be found in healthy tissue, The post Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens appeared first on Labiotech.eu.
- GSK stops studies testing closely watched cancer immunotherapyby Ned Pagliarulo on Aprile 15, 2021 at 3:15 pm
The British pharma will halt enrollment in two studies testing feladilimab alongside Merck's Keytruda, dealing another blow to the company's cancer drug pipeline.
- Thermo Fisher to buy research contractor PPD in $17B dealby Kristin Jensen on Aprile 15, 2021 at 2:59 pm
The deal values PPD at $47.50 a share, or about 24% over the company's closing price on April 13 — the day before The Wall Street Journal reported word of the planned acquisition.
- Merck, in latest COVID-19 setback, scraps one drug and pins hopes on anotherby Ben Fidler on Aprile 15, 2021 at 2:57 pm
The decision to end development of a medicine acquired in a $425 million deal last November is another disappointment for Merck's coronavirus effort, which once involved multiple drugs and vaccines.
- Merck cans one COVID-19 drug, scraps a clinical trial of anotherby Nick Paul on Aprile 15, 2021 at 12:06 pm
Merck cans one COVID-19 drug, scraps a clinical trial of another ntaylor Thu, 04/15/2021 - 08:06
- Scientists make long-lasting but controversial human-monkey embryos for medical researchby Angus Liu on Aprile 15, 2021 at 12:06 pm
Scientists make long-lasting but controversial human-monkey embryos for medical research aliu Thu, 04/15/2021 - 08:06
- GSK stops Keytruda combo trials after ICOS drug falls shortby Nick Paul on Aprile 15, 2021 at 11:07 am
GSK stops Keytruda combo trials after ICOS drug falls short ntaylor Thu, 04/15/2021 - 07:07
- CDC panel delays decision on J&J vaccine, extending pause over rare side effectby Jonathan Gardner on Aprile 14, 2021 at 10:25 pm
Advisers to the agency agreed to wait for more data before recommending new guidance, but aim to reconvene quickly to decide whether vaccinations with J&J's shot should be resumed, and for whom.